Federal Register / Vol. 75, No. 211 / Tuesday, November 2, 2010 / Notices 67377 

program. 3001 children and families in 

17 sites were randomly assigned either 

to the program group (allowed to enroll 

in EHS), or to the control group 

(precluded from enrolling in EHS, 

although they could receive other 

services in the community). Child and 

family assessments were conducted 

when children were 14 months old, 24 

months old, 36 months old, in the 

spring prior to kindergarten entry, and 

again in the spring of the sixth year of 

formal schooling (5th grade for most 

children). 

If the decision is made to follow the 

sample through high school, it is 

important to maintain contact with the 

participants so that response rates at 

follow-up points will be maximized and 

will not further deteriorate. The success 

that the contractor has in contacting the 

sample members will be taken into 

consideration in the decision whether to 

pursue further follow up. It is hoped 

that this strenuous effort in location and 

tracking will re-establish contact with 

participants who were not reached in 

the fifth grade data collection wave. 

Telephone interviews will be conducted 

in order to update the respondent’s 

location and contact information. This 

information will be collected from 

parents or guardians in the spring of 

2011. A small set of additional items 

will provide information on the parents’ 

perception of the children’s status. 

Respondents: Treatment and control 

group members in the Early Head Start 

Research and Evaluation Project. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

Tracking interview ............................................................................................ 2,700 1 0.25 675 

Estimated Total Annual Burden 

Hours: 675. 

In compliance with the requirements 

of Section 506(c)(2)(A) of the Paperwork 

Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. E-mail address: 

infocollection@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Dated: October 28, 2010. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2010–27593 Filed 11–1–10; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects: 

Title: Reunification Procedures for 

Unaccompanied Alien Children. 

OMB No.: 0970–0278. 

Description: Following the passage of 

the 2002 Homeland Security Act (Pub. 

L. 107–296), the Administration for 

Children and Families (ACF), Office of 

Refugee Resettlement (ORR), is charged 

with the care and placement of 

unaccompanied alien children in 

Federal custody, and implementing a 

policy for the release of these children, 

when appropriate, upon the request of 

suitable sponsors while awaiting 

immigration proceedings. In order for 

ORR to make determinations regarding 

the release of these children, the 

potential sponsors must meet certain 

conditions pursuant to section 462 of 

the Homeland Security Act and the 

Flores v. Reno Settlement Agreement 

No. CV85–4544–RJK (C.D. Cal. 1997). 

The proposed information collection 

requests information to be utilized by 

ORR for determining the suitability of a 

sponsor/respondent for the release of a 

minor from ORR custody. The proposed 

instruments are the Sponsors Agreement 

to Conditions of Release, Verification of 

Release, Family Reunification Packet, 

and the Authorization for Release of 

Information. 

Respondents: Sponsors requesting 

release of unaccompanied alien children 

to their custody. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

Sponsor’s Agreement to Conditions of Release ............................................. 4,288 2 0.08 686.08 

Verification of Release ..................................................................................... 4,288 1 0.17 728.96

Family Reunification Packet ............................................................................ 4,288 18 0.04 3,087.36 

Authorization for Release of Information ......................................................... 4,288 15 0.22 14,150.40 

Estimated Total Annual Burden 

Hours: 18,652.80. 

In compliance with the requirements 

of Section 506(c)(2)(A) of the Paperwork 

Reduction Act of 1995, the 

Administration for Children and 


hsrobinson on DSK69SOYB1PROD with NOTICES
67378 Federal Register / Vol. 75, No. 211 / Tuesday, November 2, 2010 / Notices 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. E-mail address: 

infocollection@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Dated: October 28, 2010. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2010–27596 Filed 11–1–10; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, Ancillary Study in 

Necrotizing Enterocolitis. 

Date: December 1, 2010. 

Time: 3 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892. (Telephone 

Conference Call) 

Contact Person: Maria E. Davila-Bloom, 

PhD, Scientific Review Officer, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 758, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

594–7637, davilabloomm@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: October 26, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–27569 Filed 11–1–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No FDA–2010–N–0001] 

Pediatric Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Pediatric 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on December 7, 2010, from 8 a.m. 

to 6 p.m. 

Location: Bethesda Marriott Hotel, 

5151 Pooks Hill Rd., Bethesda, MD 

20814. 

Contact Person: Walter Ellenberg, 

Office of Pediatric Therapeutics, Office 

of Special Medical Programs, Office of 

the Commissioner, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg 32, rm. 5154, Silver Spring, 

MD 20993, 301–796–0885, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

8732310001. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: The Pediatric Advisory 

Committee will meet to discuss 

pediatric-focused safety reviews, as 

mandated by the Best Pharmaceuticals 

for Children Act and the Pediatric 

Research Equity Act, for Prevista 

(darunavir ethanolate), PegIntron 

(peginterferon alfa–2b), Xyzal 

(levocetirizine dihydrochloride) tablet 

and solution, Flovent HFA (fluticasone 

propionate), Acanya Gel (clindamycin/ 

benzoyl peroxide combination), Epiduo 

Gel (adapalene and benzoyl peroxide), 

Ulesfia Lotion 5% (benzyl alcohol), 

Axert (almotriptan), Gardasil (human 

papillomavirus quadrivalent types 6, 11, 

16, 18, vaccine recombinant), Lamictal 

and Lamictal XR (lamotrigine), and 

Neulasta (pegfilgrastim). The committee 

will also receive a followup on 

Depakote ER (divalproex sodium). 

Committee members who participated 

in the Cardiovascular and Renal Drugs 

Advisory Committee and the 

Gastrointestinal Drugs Advisory 

Committee meetings held on July 29, 

2010, and November 5, 2010, 

respectively, will provide a brief 

summary of the meetings. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 29, 2010. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 


hsrobinson on DSK69SOYB1PROD with NOTICES